Background
LAU-0901 is a platelet-activating factor (PAF) receptor antagonist.1,2 In vivo, LAU-0901 (30, 60, and 90 mg/kg) reduces infarct volume and improves neurological function in a rat model of cerebral ischemia induced by middle cerebral artery occlusion (MCAO).1 It also reduces microglial infiltration and increases astrocytic and neuronal survival in the same model.2 LAU-0901 (30 mg/kg) alone, or in combination with atorvastatin , reduces tumor growth in a U87MG glioblastoma mouse orthotopic tumor model.3
没有评价数据